BLFS (BioLife Solutions) LT-Debt-to-Total-Asset: 0.03 (As of Mar. 2026)

What is BioLife Solutions LT-Debt-to-Total-Asset?

BioLife Solutions BLFS +4.25% 72 LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioLife Solutions's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.03.

BioLife Solutions's long-term debt to total assets ratio declined from Mar. 2025 (0.04) to Mar. 2026 (0.03). It may suggest that BioLife Solutions is progressively becoming less dependent on debt to grow their business.

BioLife Solutions (NAS:BLFS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioLife Solutions LT-Debt-to-Total-Asset Related Terms

BioLife Solutions LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioLife Solutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions LT-Debt-to-Total-Asset Chart

BioLife Solutions Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.09

0.06

0.04

0.03

BioLife Solutions Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.03	0.03	0.03	0.03

72GF Score

BioLife Solutions Inc BLFS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioLife Solutions LT-Debt-to-Total-Asset Calculation

BioLife Solutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	10.657	/	405.884
	=	0.03

BioLife Solutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	10.042	/	400.906
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

BioLife Solutions (BLFS) has a LT-Debt-to-Total-Asset of 0.03 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioLife Solutions and its competitors.

Is BioLife Solutions' LT-Debt-to-Total-Asset too high?

BioLife Solutions' current LT-Debt-to-Total-Asset is 0.03. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does BioLife Solutions' LT-Debt-to-Total-Asset compare to KMTS and AZTA?

BioLife Solutions' LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioLife Solutions and its competitors. BioLife Solutions's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioLife Solutions stock overvalued right now?

Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current LT-Debt-to-Total-Asset is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioLife Solutions (BLFS) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for BLFS:

LT-Debt-to-Total-Asset: 0.03
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies KMTS AZTA ATRC STAA NNNN PLSE ANGO XRAY OSUR LMAT ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges BJX1:Germany

Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website https://www.biolifesolutions.com

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

72GF Score

Get the complete analysis for BLFS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.64

Price

$28.57

GF Value

View BLFS Analysis

See LT-Debt-to-Total-Asset data for all stocks →